Shweta Maniar Sells 3,519 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,519 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the transaction, the director now directly owns 7,383 shares in the company, valued at approximately $227,913.21. This trade represents a 32.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shweta Maniar also recently made the following trade(s):

• On Tuesday, November 26th, Shweta Maniar sold 3,782 shares of RxSight stock. The shares were sold at an average price of $45.88, for a total value of $173,518.16.

RxSight Trading Down 2.0 %

Shares of RxSight stock opened at $31.85 on Wednesday. The stock has a fifty day simple moving average of $37.11 and a 200 day simple moving average of $45.54. RxSight, Inc. has a 12-month low of $26.29 and a 12-month high of $66.54. The company has a market capitalization of $1.28 billion, a P/E ratio of -38.37 and a beta of 1.20.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.18). The business had revenue of $35.31 million during the quarter, compared to the consensus estimate of $35.15 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. During the same quarter last year, the company earned ($0.35) EPS. On average, analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RXST. Amalgamated Bank grew its stake in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the period. Hsbc Holdings PLC bought a new position in RxSight in the 2nd quarter valued at $242,000. Public Employees Retirement Association of Colorado purchased a new position in shares of RxSight during the 2nd quarter valued at $168,000. Canada Pension Plan Investment Board purchased a new position in shares of RxSight during the 2nd quarter valued at $156,000. Finally, Bank of Montreal Can purchased a new position in shares of RxSight during the 2nd quarter valued at $5,446,000. Institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

RXST has been the subject of several recent research reports. UBS Group initiated coverage on RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective for the company. Wells Fargo & Company decreased their price objective on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Stifel Nicolaus decreased their price objective on RxSight from $40.00 to $35.00 and set a “hold” rating for the company in a report on Monday, January 13th. Jefferies Financial Group initiated coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, RxSight currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.13.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.